Open for Business: What a transatlantic free trade agreement means to the UK life sciences sector
This event will explore the changes and benefits a transatlantic trade and investment agreement can bring to the UK life sciences sector. Participants will be offered a unique platform for exchange and networking with insights from a senior expert panel including local business, international companies, government and trade associations. Full invitation can be found here. A detailed background briefing for the event can be found here.
Agenda
09.30-10.00 Registration and Networking Opportunity
10.00-10.05 Welcome by Dr Nick Scott-Ram, Oxford Academic Health Science Network (AHSN)
10.05-10.15 Introduction by Chair, Larry Stone, BT and BAB Policy & Trade Forum
10:15-10.25 David Henig, BIS on TTIP background and current status of negotiations, with references to life sciences and healthcare content, UK Government’s role, stakeholder outreach, with reference to current public debate
10.25-10.35 Joseph T. Burke, US Embassy, on US position and ambition for negotiations, with references (if possible) to sector-specific elements
10.35-10.45 Thom Thorp, Lilly, on footprint in the UK (sites, people, products etc.), importance to regions and supply chains, UK/EU-US trade and investment dimension, with particular view on trade and investment flows, hopes and engagement around TTIP, with reference to own engagement.
10.45-10.55 Andy Vardé, Owen Mumford, on company history and products. Importance of US market for exports and growth. Example(s) of necessity to comply with different regulatory regimes etc. hopes and questions regarding a future trade and investment agreement.
10.55-11.05 Peter Nolan, Oxford BioMedica, on company history and products. Importance of US market for exports and growth. Example(s) of necessity to comply with different regulatory regimes etc. hopes and questions regarding a future trade and investment agreement.
11.05-11.15 Kate Ling, NHS European Office, on role of the NHS European Office, relationship between innovation in life sciences and healthcare sector and public services. How trade and investment can benefit patients. NHS European office view on investment protection provisions discussed under TTIP, with reference to TTIP briefing paper.
11.15-11.25 Dr. Shawn Manning, Akesios Associates, on the potential impact of TTIP from a life science investor perspective
11.25-12.00 Open discussion facilitated by chair
12.00-13.00 Networking Lunch
Topics addressed in the panel discussion will include: the importance of the Life Sciences industry to Oxfordshire and the UK, the role of the sector in EU-US trade negotiations, expected changes and hopes in regards to market access, regulatory issues and tariffs, key challenges for UK companies looking to trade and invest in the US, and the role that sector business stakeholders can play in negotiation process.
Full Press Release can be found here.
Post event Press Release can be found here.
Event publication can be found here.
Event Details:
|
Date |
Thursday September 24th 2015 |
|
Time |
10:00am – 1:00pm |
|
Location |
Oxford Academic Health Science Network Magdalen Centre North, Robert Robinson Avenue Oxford Science Park OX4 4GA |
|
Attendance Fees |
Attendance by invitation only. For more information contact: Emanuel Adam Policy and Public Affairs Manager eadam@babinc.org 020 7290 9885 |
